BREAKING NEW GROUNDS IN DIABETES CARE
According to the American Diabetes Association, millions of people around the world live with diabetes or know someone living with diabetes. No type of diabetes is curable yet; however, it is a very treatable disease, and no matter how frightening, annoying, and frustrating it can be, people with diabetes can live long, healthy, and happy lives. Our goal is to provide you the information, tools, and resources to help make that happen.
In a recent statistics report from CDC National Diabetes Statistics, diabetes remains the 7th leading cause of death in the United States in 2015, with 79,535 death certificates listing it as the underlying cause of death and a total of 252,806 death certificates listing diabetes as an underlying or contributing cause of death.
With numerous methods on the market for managing and treating diabetes, there is one product that is a cut above the others when it comes to diabetes care–D’OXYVA by Circularity Healthcare. Setting a new paradigm in health science, D’OXYVA is a truly unique technology at its core, a first-of-its-kind biotech solution clinically validated to significantly lower the risk of diabetes and cardiovascular complications.
Circularity Healthcare was recently selected for the list of “Top 10 Diabetes Care Solution Providers of 2018” in the upcoming November Diabetes Carespecial edition of MedTech Outlook magazine after receiving more than 270 unique nominations from more than 39,000 qualified print and 66,000 qualified digital subscribers. The magazine does not rank the top ten providers; it lists them in alphabetical order on a full page. In addition, the magazine will run a featured article on Circularity and its D’OXYVA product line in the same special edition this November.
The future holds favorable prospects for Circularity Healthcare. They are expecting continued commercial growth with D’OXYVA, with other major announcements to follow shortly in multiple leading media outlets in the US and around the world as Circularity’s global marketing and PR campaign based on years of yet–unpublished highly successful clinical evidence unfolds in the coming weeks and months.
At the end of it all, D’OXYVA is indeed a revolutionary and a much-needed step toward a powerful and safe diabetes care solution that is adding immeasurable value to health outcomes.
December 2018 digital issue of MedTech Outlook: https://www.medicaltechoutlook.com/magazines/December2018/Diabetes_Care
Clinical studies with D’OXYVA® (deoxyhemoglobin vasodilator) have shown extraordinary results for the role of transdermal noninvasive wound care using ultra-purified, nontoxic, FDA-cleared molecules, such as CO2, especially when all other approaches failed.
In an ongoing multiyear, multi-country, multicenter, randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks**.